Resection of oesophageal and oesophagogastric junction cancer liver metastases - a summary of current evidence.
Liver metastases
Liver resection
Metastasectomy
Multimodal treatment
Oesophageal cancer
Oesophagogastric junction cancer
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
08
10
2021
accepted:
23
11
2021
pubmed:
4
12
2021
medline:
3
6
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Metastatic oesophageal cancer is commonly considered as a palliative situation with a poor prognosis. However, there is increasing evidence that well-selected patients with a limited number of liver metastases (ECLM) may benefit from a multimodal approach including surgery. A systematic review of the current literature for randomized trials, retrospective studies, and case series with patients undergoing hepatectomies for oesophageal and oesophagogastric junction cancer liver metastases was conducted up to the 31st of August 2021 using the MEDLINE (PubMed) and Cochrane Library databases. A total of 661 articles were identified. After removal of duplicates, 483 articles were screened, of which 11 met the inclusion criteria. The available literature suggests that ECLM resection in patients with liver oligometastatic disease may lead to improved survival and even long-term survival in some cases. The response to concomitant chemotherapy and liver resection seems to be of significance. Furthermore, a long disease-free interval in metachronous disease, low number of liver metastases, young age, and good overall performance status have been described as potential predictive markers of outcome for the resection of liver metastases. Surgery may be offered to carefully selected patients to potentially improve survival rates compared to palliative treatment approaches. Studies with standardized patient selection criteria and treatment protocols are required to further define the role for surgery in ECLM. In this context, particular consideration should be given to neoadjuvant treatment concepts including immunotherapies in stage IVB oesophageal and oesophagogastric junction cancer.
Identifiants
pubmed: 34860291
doi: 10.1007/s00423-021-02387-3
pii: 10.1007/s00423-021-02387-3
pmc: PMC9151540
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
947-955Informations de copyright
© 2021. The Author(s).
Références
Van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, SpillenaarBilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A, CROSS Group (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084. https://doi.org/10.1056/NEJMoa1112088 (PMID: 22646630)
doi: 10.1056/NEJMoa1112088
pubmed: 22646630
Donlon NE, Ravi N, King S, Cunninhgam M, Cuffe S, Lowery M, Wall C, Hughes N, Muldoon C, Ryan C, Moore J, O’Farrell C, Gorry C, Duff AM, Enright C, Nugent TS, Elliot JA, Donohoe CL, Reynolds JV (2021) Modern oncological and operative outcomes in oesophageal cancer: the St. James’s hospital experience. Ir J Med Sci 190:297–305. https://doi.org/10.1007/s11845-020-02321-4 (PMID: 32696244)
doi: 10.1007/s11845-020-02321-4
pubmed: 32696244
Janmaat VT, Steyerberg EW, van der Gaast A, Mathijssen RH, Bruno MJ, Peppelenbosch MP, Kuipers EJ, Spaander MC (2017) Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer. Cochrane Database Syst Rev 11:004063. https://doi.org/10.1002/14651858.CD004063.pub4 (PMID: 29182797)
doi: 10.1002/14651858.CD004063.pub4
Procopio F, Marano S, Gentile D, Da Roit A, Basato S, Riva P, De Vita F, Torzilli G, Castoro C (2019) Management of liver oligometastatic esophageal cancer: overview and critical analysis of the different loco-regional treatments. Cancers (Basel) 12:20. https://doi.org/10.3390/cancers12010020 (PMID: 31861604)
doi: 10.3390/cancers12010020
Seesing MFJ, van der Veen A, Brenkman HJF, Stockmann HBAC, Nieuwenhuijzen GAP, Rosman C, van den Wildenberg FJH, van Berge Henegouwen MI, van Duijvendijk P, Wijnhoven BPL, Stoot JHMB, Lacle M, Ruurda JP, van Hillegersberg R, Gastroesophageal Metastasectomy Group (2019) Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Dis Esophagus 32:doz034. https://doi.org/10.1093/dote/doz034 (PMID: 31220859)
doi: 10.1093/dote/doz034
pubmed: 31220859
pmcid: 7705435
Filmann N, Walter D, Schadde E, Bruns C, Keck T, Lang H, Oldhafer K, Schlitt HJ, Schön MR, Herrmann E, Bechstein WO, Schnitzbauer AA (2019) Mortality after liver surgery in Germany. Br J Surg 106:1523–1529. https://doi.org/10.1002/bjs.11236 (PMID: 31339558)
doi: 10.1002/bjs.11236
pubmed: 31339558
Farges O, Goutte N, Bendersky N, Falissard B, ACHBT-French Hepatectomy Study Group (2012) Incidence and risks of liver resection: an all-inclusive French nationwide study. Ann Surg 256:697–704. https://doi.org/10.1097/SLA.0b013e31827241d5 (discussion 704-5 PMID: 23095612)
doi: 10.1097/SLA.0b013e31827241d5
pubmed: 23095612
Angelsen JH, Horn A, Sorbye H, Eide GE, Løes IM, Viste A (2017) Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. Br J Surg 104:580–589. https://doi.org/10.1002/bjs.10457 (PMID: 28181674)
doi: 10.1002/bjs.10457
pubmed: 28181674
Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–25 (discussion 825-7 [PMID: 15166961 00000658-200406000-00009])
doi: 10.1097/01.sla.0000128305.90650.71
Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240:438–47 (discussion 447-50 [PMID: 15319715 00000658-200409000-00005])
doi: 10.1097/01.sla.0000138076.72547.b1
Ichida H, Imamura H, Yoshimoto J, Sugo H, Kajiyama Y, Tsurumaru M, Suzuki K, Ishizaki Y, Kawasaki S (2013) Pattern of postoperative recurrence and hepatic and/or pulmonary resection for liver and/or lung metastases from esophageal carcinoma. World J Surg 37:398–407. https://doi.org/10.1007/s00268-012-1830-7 (PMID: 23142988)
doi: 10.1007/s00268-012-1830-7
pubmed: 23142988
Huddy JR, Thomas RL, Worthington TR, Karanjia ND (2015) Liver metastases from esophageal carcinoma: is there a role for surgical resection? Dis Esophagus 28:483–487. https://doi.org/10.1111/dote.12233 (PMID: 24898890)
doi: 10.1111/dote.12233
pubmed: 24898890
Van Daele E, Scuderi V, Pape E, Van de Putte D, Varin O, Van Nieuwenhove Y, Ceelen W, Troisi R, Pattyn P (2018) Long-term survival after multimodality therapy including surgery for metastatic esophageal cancer. Acta Chir Belg 118:227–232. https://doi.org/10.1080/00015458.2017.1411557 (PMID: 29258384)
doi: 10.1080/00015458.2017.1411557
pubmed: 29258384
Tanaka T, Fujita H, Matono S, Nagano T, Nishimura K, Murata K, Shirouzu K, Suzuki G, Hayabuchi N, Yamana H (2010) Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org). Dis Esophagus 23:646–651. https://doi.org/10.1111/j.1442-2050.2010.01069.x (PMID: 20545979)
doi: 10.1111/j.1442-2050.2010.01069.x
pubmed: 20545979
Schauer M, Stein H, Lordick F, Feith M, Theisen J, Siewert JR (2008) Results of a multimodal therapy in patients with stage IV Barrett’s adenocarcinoma. World J Surg 32:2655–2660. https://doi.org/10.1007/s00268-008-9722-6 (PMID: 18802733)
doi: 10.1007/s00268-008-9722-6
pubmed: 18802733
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, ArbeitsgruppeLebermetastasen und–tumoren in der ChirurgischenArbeitsgemeinschaftOnkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD) (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 14:1208–1215 ([PMID: 24120480 S1470-2045(13)70447-9])
doi: 10.1016/S1470-2045(13)70447-9
Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, Clancy TE (2017) Management of neuroendocrine tumor liver metastases: long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol 24:2319–2325. https://doi.org/10.1245/s10434-017-5839-x (PMID: 28303430)
doi: 10.1245/s10434-017-5839-x
pubmed: 28303430
Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, Jaeck D, Saric J, Le Treut YP, Belghiti J, Mantion G, Mentha G, Association Française de Chirurgie (2006) Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 244:524–535 ([PMID: 16998361 00000658-200610000-00007])
doi: 10.1097/01.sla.0000246847.02058.1b
Weitz J, Blumgart LH, Fong Y, Jarnagin WR, D’Angelica M, Harrison LE, DeMatteo RP (2005) Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma. Ann Surg 241:269–276 ([PMID: 15650637 00000658-200502000-00012])
doi: 10.1097/01.sla.0000150244.72285.ad
Gandy RC, Bergamin PA, Haghighi KS (2017) Hepatic resection of non-colorectal non-endocrine liver metastases. ANZ J Surg 87:810–814. https://doi.org/10.1111/ans.13470 (PMID: 27037839)
doi: 10.1111/ans.13470
pubmed: 27037839
Slotta JE, Schuld J, Distler S, Richter S, Schilling MK, Kollmar O (2014) Hepatic resection of non-colorectal and non-neuroendocrine liver metastases - survival benefit for patients with non-gastrointestinal primary cancers - a case-controlled study. Int J Surg 12:163–168 ([PMID: 24342081 S1743-9191(13)01124-2])
doi: 10.1016/j.ijsu.2013.12.002
Fitzgerald TL, Brinkley J, Banks S, Vohra N, Englert ZP, Zervos EE (2014) The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbecks Arch Surg 399:989–1000. https://doi.org/10.1007/s00423-014-1241-3 (PMID: 25148767)
doi: 10.1007/s00423-014-1241-3
pubmed: 25148767
Bresadola V, Rossetto A, Adani GL, Baccarani U, Lorenzin D, Favero A, Bresadola F (2011) Liver resection for noncolorectal and nonneuroendocrine metastases: results of a study on 56 patients at a single institution. Tumori 97:316–322. https://doi.org/10.1700/912.10028 (PMID: 21789009)
doi: 10.1700/912.10028
pubmed: 21789009
Carmona-Bayonas A, Jiménez-Fonseca P, Echavarria I, Sánchez Cánovas M, Aguado G, Gallego J, Custodio A, Hernández R, Viudez A, Cano JM, AGAMENON Study Group (2018) Surgery for metastases for esophageal-gastric cancer in the real world: data from the AGAMENON national registry. Eur J Surg Oncol 44:1191–1198. https://doi.org/10.1016/j.ejso.2018.03.019 (PMID: 29685755)
doi: 10.1016/j.ejso.2018.03.019
pubmed: 29685755
Schmidt T, Alldinger I, Blank S, Klose J, Springfeld C, Dreikhausen L, Weichert W, Grenacher L, Bruckner T, Lordick F, Ulrich A, Büchler MW, Ott K (2015) Surgery in oesophago-gastric cancer with metastatic disease: treatment, prognosis and preoperative patient selection. Eur J Surg Oncol 41:1340–1347 ([PMID: 26213358 S0748-7983(15)00436-9])
doi: 10.1016/j.ejso.2015.05.005
Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, Mansfield P, Ajani J (2015) Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol 111:875–881. https://doi.org/10.1002/jso.23907 (PMID: 25872485)
doi: 10.1002/jso.23907
pubmed: 25872485
Andreou A, Viganò L, Zimmitti G, Seehofer D, Dreyer M, Pascher A, Bahra M, Schoening W, Schmitz V, Thuss-Patience PC, Denecke T, Puhl G, Vauthey JN, Neuhaus P, Capussotti L, Pratschke J, Schmidt SC (2014) Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer. J Gastrointest Surg 18:1974–1986. https://doi.org/10.1007/s11605-014-2623-0 (PMID: 25159501)
doi: 10.1007/s11605-014-2623-0
pubmed: 25159501
Depypere L, Lerut T, Moons J, Coosemans W, Decker G, Van Veer H, De Leyn P, Nafteux P (2017) Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus 30:1–8. https://doi.org/10.1111/dote.12508 (PMID: 27704661)
doi: 10.1111/dote.12508
pubmed: 27704661
Parry K, Visser E, van Rossum PS, Mohammad NH, Ruurda JP, van Hillegersberg R (2015) Prognosis and treatment after diagnosis of recurrent esophageal carcinoma following esophagectomy with curative intent. Ann Surg Oncol 22(Suppl 3):S1292-300. https://doi.org/10.1245/s10434-015-4840-5 (PMID: 26334295)
doi: 10.1245/s10434-015-4840-5
pubmed: 26334295
Ichikawa H, Kosugi S, Nakagawa S, Kanda T, Tsuchida M, Koike T, Tanaka O, Hatakeyama K (2011) Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery 149:164–170. https://doi.org/10.1016/j.surg.2010.07.047 (PMID: 20817205)
doi: 10.1016/j.surg.2010.07.047
pubmed: 20817205
Kanamori J, Aokage K, Hishida T, Yoshida J, Tsuboi M, Fujita T, Nagino M, Daiko H (2017) The role of pulmonary resection in tumors metastatic from esophageal carcinoma. Jpn J Clin Oncol 47:25–31. https://doi.org/10.1093/jjco/hyw141 (PMID: 27655907)
doi: 10.1093/jjco/hyw141
pubmed: 27655907
Wang J, Suri JS, Allen PK, Liao Z, Komaki R, Ho L, Hofstetter WL, Lin SH (2016) Factors predictive of improved outcomes with multimodality local therapy after palliative chemotherapy for stage IV esophageal cancer. Am J Clin Oncol 39:228–235. https://doi.org/10.1097/COC.0000000000000066 (PMID: 24710122)
doi: 10.1097/COC.0000000000000066
pubmed: 24710122
Liu J, Wei Z, Wang Y, Xia Z, Zhao G (2018) Hepatic resection for post-operative solitary liver metastasis from oesophageal squamous cell carcinoma. ANZ J Surg 88:E252–E256. https://doi.org/10.1111/ans.13810 (PMID: 27764891)
doi: 10.1111/ans.13810
pubmed: 27764891
Kobayashi N, Kohno T, Haruta S, Fujimori S, Shinohara H, Ueno M, Udagawa H (2014) Pulmonary metastasectomy secondary to esophageal carcinoma: long-term survival and prognostic factors. Ann Surg Oncol 21(Suppl 3):S365-9. https://doi.org/10.1245/s10434-014-3677-7 (PMID: 24796966)
doi: 10.1245/s10434-014-3677-7
pubmed: 24796966
Shiono S, Kawamura M, Sato T, Nakagawa K, Nakajima J, Yoshino I, Ikeda N, Horio H, Akiyama H, Kobayashi K, Metastatic Lung Tumor Study Group of Japan (2008) Disease-free interval length correlates to prognosis of patients who underwent metastasectomy for esophageal lung metastases. J Thorac Oncol 3:1046–1049. https://doi.org/10.1097/JTO.0b013e318183aa0c (PMID: 18758309)
doi: 10.1097/JTO.0b013e318183aa0c
pubmed: 18758309
Chao YK, Wu YC, Liu YH, Tseng CK, Chang HK, Hsieh MJ, Chu Y, Liu HP (2010) Distant nodal metastases from intrathoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after chemoradiotherapy. J Surg Oncol 102:158–62. https://doi.org/10.1002/jso.21588 (PMID: 20648587)
doi: 10.1002/jso.21588
pubmed: 20648587
DeSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, Herrmann K, Lecouvet FE (2018) Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 91:153–163 ([PMID: 29331524 S0959-8049(17)31491-0])
doi: 10.1016/j.ejca.2017.12.012
Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–66. https://doi.org/10.1148/radiol.09090021 (PMID: 20032142)
doi: 10.1148/radiol.09090021
pubmed: 20032142
Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-Bergkamen H, Jäger D, Büchler M, Siewert JR, Ott K (2013) A reliable risk score for stage IV esophagogastric cancer. Eur J Surg Oncol 39:823–830 ([PMID: 23375470 S0748-7983(13)00007-3])
doi: 10.1016/j.ejso.2013.01.005
Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD (2017) Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 3:1237–1244. https://doi.org/10.1001/jamaoncol.2017.0515 (PMID: 28448662)
doi: 10.1001/jamaoncol.2017.0515
pubmed: 28448662
pmcid: 5824287
Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP (2017) The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI. BMC Cancer 17:893. https://doi.org/10.1186/s12885-017-3918-9 (PMID: 29282088)
doi: 10.1186/s12885-017-3918-9
pubmed: 29282088
pmcid: 5745860
Cancer Genome Atlas Research Network (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541:169–175. https://doi.org/10.1038/nature20805 (PMID: 28052061)
doi: 10.1038/nature20805
Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U (2001) Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234:360–7 (discussion 368-9 [PMID: 11524589 0000658-200109000-00010])
doi: 10.1097/00000658-200109000-00010
Stein HJ, Feith M, Bruecher BL, Naehrig J, Sarbia M, Siewert JR (2005) Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 242:566–73 (discussion 573-5 [PMID: 16192817 00000658-200510000-00012])
doi: 10.1097/01.sla.0000184211.75970.85